Journal issues > Issue 4, August 2017 > Novelties in the treatment of classical Hodgkin lymphoma

Novelties in the treatment of classical Hodgkin lymphoma

SUMMARY

Practice changing novelties in the treatment of classical Hodgkin lymphoma (cHL) were scarce at EHA 2017. This summary will discuss three abstracts presented during an oral session dedicated to clinical findings in Hodgkin (HL) and indolent Non-Hodgkin Lymphoma (iNHL).

(BELG J HEMATOL 2017;8(4):141–3)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €2.42

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top